Last updated on November 2017

A Phase 4 clinical study for patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who experience COPD exacerbations.


Brief description of study

A Phase 4 clinical study for patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who experience COPD exacerbations.

Detailed Study Description

This study will be a double-blind, randomized, placebo controlled, parallel-group study to evaluate the effect of Aclidinium bromide on the cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD, as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (GOLD, 2011). The objectives of this study are to assess the safety of Aclidinium bromide on major adverse cardiovascular events (MACE), to assess the overall safety of Aclidinium bromide and to assess whether Aclidinium bromide reduces moderate or severe COPD exacerbations.

Clinical Study Identifier: TX81390

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Pensacola Research Consultants Inc.

Pensacola Research Consultants Inc.
Pensacola, FL USA
  Connect »